Etilefrine

Etilefrine

Clinical data
ATC code	C01CA01 (WHO)
Identifiers
IUPAC name 3-(2-ethylamino-1-hydroxyethyl)phenol
PubChem CID	3306
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C10H15NO2
Molar mass	181.232 g/mol

WikiDoc Resources for Etilefrine
Articles
Most recent articles on Etilefrine Most cited articles on Etilefrine Review articles on Etilefrine Articles on Etilefrine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Etilefrine Images of Etilefrine Photos of Etilefrine Podcasts & MP3s on Etilefrine Videos on Etilefrine
Evidence Based Medicine
Cochrane Collaboration on Etilefrine Bandolier on Etilefrine TRIP on Etilefrine
Clinical Trials
Ongoing Trials on Etilefrine at Clinical Trials.gov Trial results on Etilefrine Clinical Trials on Etilefrine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Etilefrine NICE Guidance on Etilefrine NHS PRODIGY Guidance FDA on Etilefrine CDC on Etilefrine
Books
Books on Etilefrine
News
Etilefrine in the news Be alerted to news on Etilefrine News trends on Etilefrine
Commentary
Blogs on Etilefrine
Definitions
Definitions of Etilefrine
Patient Resources / Community
Patient resources on Etilefrine Discussion groups on Etilefrine Patient Handouts on Etilefrine Directions to Hospitals Treating Etilefrine Risk calculators and risk factors for Etilefrine
Healthcare Provider Resources
Symptoms of Etilefrine Causes & Risk Factors for Etilefrine Diagnostic studies for Etilefrine Treatment of Etilefrine
Continuing Medical Education (CME)
CME Programs on Etilefrine
International
Etilefrine en Espanol Etilefrine en Francais
Business
Etilefrine in the Marketplace Patents on Etilefrine
Experimental / Informatics
List of terms related to Etilefrine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Etilefrine is a cardiac stimulant used as an antihypotensive. It is a sympathomimetic amine of the 3-hydroxy-phenylethanolamine series used in treating orthostatic hypotension of neurological, cardiovascular, endocrine or metabolic origin. Intravenous infusion of this compound increases cardiac output, stroke volume, venous return and blood pressure in man and experimental animals, suggesting stimulation of both α and β adrenergic receptors. However, in vitro studies indicate that etilefrine has a much higher affinity for β₁ (cardiac) than for β₂ adrenoreceptors.

Intravenous etilefrine increases the pulse rate, cardiac output, stroke volume, central venous pressure and mean arterial pressure of healthy individuals. Peripheral vascular resistance falls during the infusion of 1–8 mg etilefrine but begins to rise at higher dosage. Marked falls in pulse rate, cardiac output, stroke volume and peripheral bloodflow, accompanied by rises in mean arterial pressure, occur when etilefrine is infused after administration of intravenous propranolol 2,5 mg. These findings indicate that etilefrine has both β₁ and α₁ adrenergic effects in man.